1. Home
  2. JSPR vs CTSO Comparison

JSPR vs CTSO Comparison

Compare JSPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

48.1M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.68

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
CTSO
Founded
2018
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.1M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JSPR
CTSO
Price
$2.05
$0.68
Analyst Decision
Buy
Buy
Analyst Count
11
2
Target Price
$21.44
$5.38
AVG Volume (30 Days)
658.5K
139.8K
Earning Date
02-26-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,979,520.00
Revenue This Year
N/A
$7.26
Revenue Next Year
N/A
$9.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$1.39
$0.60
52 Week High
$21.27
$1.61

Technical Indicators

Market Signals
Indicator
JSPR
CTSO
Relative Strength Index (RSI) 62.61 49.64
Support Level $1.73 $0.62
Resistance Level $1.85 $0.68
Average True Range (ATR) 0.11 0.05
MACD 0.03 0.00
Stochastic Oscillator 97.70 48.48

Price Performance

Historical Comparison
JSPR
CTSO

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: